1. Zhou J., Nozari A., Bateman B., Allen P.D., Pessah I.N. Neuromuscular Disorders Including Malignant Hyperthermia and Other Genetic Disorders. In: Miller's Anesthesia, 2-Volume Set 9th Edition. – Elsevier, 2020. – Pp.1113-1144. 2. Ruffert H., Bastian B., Bendixen D. et al., on behalf of the European Malignant Hyperthermia Group. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. British Journal of Anaesthesia, 2021; 126 (1): 120e130. doi: 10.1016/j.bja.2020.09.029 3. Johnson C., Edlemann K.J. Malignant hyperthermia: A review. J. Perinatol. 1992; 12: 61-71. 4. Levitt R.C. Prospects for the diagnosis of malignant hyperthermia susceptibility using molecular genetic approaches. Anesthesiology 1992; 76: 1039-1048. 5. MacLennan D.H., Phillips M.S. Malignant hyperthermia. Science 1992; 256: 789-794. 6. Williams C.H., Lasley J.H. The mode of inheritance of the fulminant hyperthermia stress syndrome in swine. In Henschel E.O., ed: Malignant hyperthermia: current concepts. New York, Appleton-Century-Crofts, 1977. – P. 141. 7. Bell C., Kain Z.N., ed: The Pediatric Anesthesia Handbook, 2nd Edition, St. Louis, MosbyYear Book, 1997. – Pp. 485-500 26 8. Wappler F. Malignant hyperthermia. Eur. J. Anaesth. 2001; 18: 632–652. 9. Hopkins P.M. Malignant hyperthermia: pharmacology of triggering. Br. J. Anaesth. 2011; 107: 48e56. 10. Glahn K.P., Ellis F.R., Halsall P.J. et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br. J. Anaesth. 2010; 105: 417e20. 11. Recommandations d’Experts pour le Risque d’ l’Hyperthermie Maligne en Anesthésie Réanimation, Société Française d’Anesthésie et de Réanimation (2013). Режим доступа: https://sfar.org/wp-content/uploads/2015/10/2_SFAR_HyperthermieMaligne.pdf (доступ 16/07/2023). 12. Glahn K.P.E., Bendixen D., Girard T. et al. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br. J. Anaesth. 2020; 125: 133e40. 13. Prise en charge de l’Hyperthermie Maligne. Actualisation de recommandations de Pratiques Professionnelles, Société Française d’Anesthésie et de Réanimation (2019). Режим доступа: https://sfar.org/download/rpp-hyperthermie-maligne/?wpdmdl=24495&refresh=64b3dba8732861689508776 (доступ 16/07/2023). 14. Preventing malignant hyperthermia: an anesthesia protocol, Malignant Hyperthermia Association of the United States (MHAUS), 1993. 15. Gronert G.A. Human malignant hyperthermia: Awake episodes and correction with dantrolene. Anesth. Analg 1980: 59; 377-378. 16. Strazis K.P., Fox A.W. Malignant hyperthermia: a review of published cases. Anesth. Analg. 1993; 77: 297-304. 17. Britt B.A. Recent advances in malignant hyperthermia. Anest Analg 1972;51:841-850. 18. Relton J.E., Britt B.A., Steward D.J. Malignant hyperpyrexia. Br. J. Anaesth. 1973; 45: 269- 275. 19. Rosenberg H., Fletcher J.E. Malignant hyperthermia. In Barash P.G., ed: ASA Refresher Courses in Anesthesiology, vol 14. Philadelphia, JB Lippincott Co., 1986. – Pp. 207-216. 20. Kim D.-C. Malignant hyperthermia. Korean J. Anesthesiol. 2012 Nov;63(5): 391-401. 21. Ording H. Incidence of malignant hyperthermia in Denmark. Anesth. Analg. 1985; 64: 700-704. 22. Rosenberg H., Davis M., James D., Pollock N., Stowell K. Malignant hyperthermia. Orphanet J. of Rare Dis. 2007; 2: 21. — doi:10.1186/1750-1172-2-21 23. Brady J.E., Sun L.S., Rosenberg H., Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005 Anesth. Analg. 2009; 109: 1162-1166. 27 24. Mayhew J.F., Rudolph J., Tobey R.E. Malignant hyperthermia in a six month old infant: a case report. Anesth. Analg. 1978; 57: 262. 25. Schmitt H.P., Simmendinger H.J., Wagner H. et al. Severe morphological changes in skeletal muscles of a five-month old infant dying from an anesthetic complication with general muscle rigidity. Neuropȁdiatrie 1975; 6: 102. 26. Heiman-Pattersohn T.H., Natter H., Rosenberg H. et al. Malignant hyperthermia susceptibility in x-linked muscle dystrophies. Pediatr. Neurol. 1987; 2: 356. 27. Schulman S. Malignant hyperthermia and pediatric anesthesia. Semin. Anesth. 1993; 12: 54-64. 28. Stamm D.S., Aylsworth A.S., Stajich J.M. et al. Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. Am. J. Med. Genet. A. 2008; 146A: 1832e41 29. Brownell A.K.W. Malignant hyperthermia: Relationship to other diseases. Br. J. Anaesth. 1988; 60: 303-308. 30. Klingler W., Rueffert H., Lehmann-Horn F., Girard T., Hopkins P.M. Core myopathies and the risk of malignant hyperthermia. Anesth. Analg. 2009; 109: 1167e73 31. Dlamini N., Voermans N.C., Lillis S. et al. Mutationsin RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul. Disord. 2013; 23: 540e8 32. Wappler F., Fiege M., Steinfath M. et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001; 94: 95e100 33. Kolb M.E., Horne M.L., Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982; 56: 254-262. 34. Kaplan R.F. Malignant hyperthermia, ASA Refresher Courses in Anesthesiology. Philadelphia, JB Lippincott Co.,1994. 35. Hannallah R.S., Kaplan R.F. Jaw relaxation after a halothane/succinylcholine sequence in children. Anesthesiology 1994; 81: 99-103. 36. Larach M.G., Rosenberg H., Larach D.R., Broennle A.M. Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology 1987; 66: 547-550. 37. Littleford J.A., Patel M.A., Bose D., Cameron C.B., McKillop C. Masseter muscle spasm in children: implications of continuing the triggering anesthetic. Anesth. Analg. 1991; 72: 151- 160. 38. O’Flinn R.P., Shutack J.G., Rosenberg H., Fletcher J.E. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients: an update on management and diagnosis. Anesthesiology 1994; 80: 1228-1233. 39. Schwartz L., Rockoff M.A., Koka B.V. Masseter spasm with anesthesia: incidence and implications. Anesth. Analg. 1991; 72: 151-160. 28 40. Barlow M.B., Isaacs H. Malignant hyperpyrexial deaths in a family – Reports of three cases. Br. J. Anesth. 1970;.42: 1072-1076. 41. Larach M.G., Brandom B.W., Allen G.C., Gronert G.A., Lehman E.B. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: A report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesth. Analg. Epub 2014 September 26. 42. Guze B.H., Baxter L.R. Neuroleptic malignant syndrome. N. Eng. J. Med. 1985; 313:163-166. 43. Larach M.G., Localio A.R., Allen G.C. et al. A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility. Anesthesilogy. – 1994; 80: 771–779. 44. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br. J. of Anaesth. 2021; 126 (1): 120e130 45. Sessler D.I. Temperature regulation. In Gregory G.A., ed: Pediatric Anesthesia, 3rd Edition, New York, Churchill Livingstone Inc., 1994. – Pp. 47-59. 46. Hopkins P.M., Girard T., Dalay S. et al. Malignant hyperthermia 2020. Guideline from the Association of Anaesthetists. Anaesthesia 2021, 76, 655–664. doi:10.1111/anae.15317 47. Hopkins P.M., Ruffert H., Snoeck M.M. et al., on behalf of The European Malignant Hyperthermia Group. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br. J. Anaesth. 2015; 115(4): 531-539. doi: 10.1093/bja/aev225 48. Larach M.G. for the North American Malignant Hyperthermia Group: Standardization of the caffeine halothane muscle contracture test. Anesth. Analg. 1989; 69: 511-515. 49. Urwyler A., Censier K., Kaufmann M.A., Drewe J. Genetic effects on the variability of the caffeine halothane muscle contracture test. Anesthesiology 1994; 80: 1287-1295. 50. Wedel D.J., Nelson T.E. Malignant hyperthermia: diagnostic dilemma – false-negative contracture responses with halothane and caffeine alone. Anesth. Analg. 1994; 78: 787-792. 51. Larach M.G., Gronert G.A., Allen G.C., Brandom B.W., Lehman E.B. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth. Analg. 2010; 110: 498e507 52. Wappler F. S1-leitlinie maligne hyperthermie: update 2018. Anaesthesist 2018; 67: 529e32 53. Лебединский К.М., Мазурок В.А., Карелов А.Е. и соавт. Гемодинамические осложнения операции и анестезии. В кн.: Кровообращение и анестезия. Под ред. Лебединского К.М., 2-е изд. – СПб.: Человек, 2015. – С. 565-698. 29 54. S1-leitlinie: Therapie der malignen Hyperthermie. Revidierte Version. DGAIinfo, 2018. Режим доступа: https://register.awmf.org/assets/guidelines/001-008l_S1_Therapie-maligne-Hyperthermie_2018-03_1.pdf (доступ 16/07/2023). 55. Riazi S., Kraeva N., Hopkins P.M. Updated guide for the management of malignant hyperthermia. Can. J. Anesth. 2018; 65: 709–721. https://doi.org/10.1007/s12630-018-1108-0 56. Racca F., Mongini T., Wolfler A., Vianello A., Cutrera R., Del Sorbo L., Capello E.C., Gregoretti C., Massa R., De Luca D., Conti G., Tegazzin V., Toscano A., Ranieri V.M. Recommendations for anesthesia and perioperative management of patients with neuromuscular disorders. Minerva Anestesiol. 2013 Apr; 79(4): 419-33. 57. Managing a Crisis: American Malignant Hyperthermia Association (MHAUS) Recommendations. Режим доступа: https://www.mhaus.org/healthcare-professionals/managing-a-crisis/ (доступ 16/07/2023). 58. Reber A., Schumacher P., Urwyler A, Effects of three different types of management on the elimination kinetics of volatile anesthetics. Anaesthesia 1993; 48: 862-865. 59. Dynasthetics. Prepare any anesthesia machine for susceptible patients in less than 90 seconds. Available from: https://www.dynasthetics.com; Accessed 28 July 2020. 60. Bennett M.H., Wainwright A.P. Acute thyroid crisis on induction of anaesthesia. Anaesthesia 1989; 44: 28-30. https://doi.org/10.1111/j.1365-2044.1989.tb11093.x 61. Caroff S.N., Roberts C.B., Rosenberg H. et al. Intravenous dantrolene in hypermetabolic syndromes: a survey of the U.S. Veterans Health Administration database. BMC Anesthesiol 2022; 22: 298. https://doi.org/10.1186/s12871-022-01841-z 62. Ryan J.F. Malignant hyperthermia: treatment and after care. Anesth. Clin. North. Am. 1991; 4: 913-932. 63. Young C.C., Sladen R.N. Hyperthermia. In: Complications in Anesthesia, 2nd ed. J.L. Atlee (ed.), 2007. – Pp. 423–426. 64. Поллард Б.Дж. Руководство по клинической анестезиологии: Пер. с англ. Под общ. ред. Л.В. Колотилова, ВВ. Мальцева. М.: МЕДпресс-информ, 2006. – 912 с. 65. Litman R.S., Smith V.I., Larach M.G. et al. Consensus statement of the Malignant Hyperthermia Association of the United States on unresolved clinical questions concerning the management of patients with malignant hyperthermia. Anesth. Analg. 2019; 128: 652e9 66. Jones P.M., Allen B.N., Cherry R.A. et al. Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study. Can. J. Anaesth. 2019; 66: 161e81 30 67. Jones C., Bennett K., Kim T.W., Bulger T.F., Pollock N. Preparation of Datex-Ohmeda Aestiva and Aisys anaesthetic machines for use in malignant hyperthermia susceptible patients. Anaesth. Intensive Care 2012; 40: 490e7 68. Kim T.W., Wingate J.R., Fernandez A.M., Whitaker E., Tham R.Q. Washout times of desflurane, sevoflurane and isoflurane from the GE Healthcare Aisys® and Avance®, Carestation®, and Aestiva® anesthesia system. Paediatr. Anaesth. 2013; 23: 1124e30 69. Kim T.W., Nemergut M.E. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice. Anesthesiology 2011; 114: 205e12 70. Petroz G.C., Lerman J. Preparation of the Siemens KION anesthetic machine for patients susceptible to malignant hyperthermia. Anesthesiology 2002; 96: 941e6 71. Prinzhausen H., Crawford M.W., O’Rourke J., Petroz G.C. Preparation of the Dräger Primus anesthetic machine for malignant hyperthermia-susceptible patients. Can. J. Anesth. 2006; 53: 885e90 72. Beebe J.J., Sessler D.I. Preparation of anesthesia machines for patients susceptible to malignant hyperthermia. Anesthesiology 1988; 69: 395e400 73. McGraw T.T., Keon T.P. Malignant hyperthermia and the clean machine. Can. J. Anesth. 1989; 36: 530e2 74. Schonell L.H., Sims C., Bulsara M. Preparing a new generation anaesthetic machine for patients susceptible to malignant hyperthermia. Anaesth. Intensive Care 2003; 31: 58e62